$3.98
0.06[1.53%]
At close: Apr 18
$3.98
0[0.00%]
PreMarket: 7:12AM EDT
AbCellera Biologics
(NASDAQ:ABCL)AbCellera Biologics Stock (NASDAQ:ABCL), Analyst Ratings, Price Targets, Predictions
AbCellera Biologics Inc has a consensus price target of $17.82, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Stifel, and Keybanc on February 22, 2024, February 21, 2024, and December 5, 2023. With an average price target of $7.67 between Benchmark, Stifel, and Keybanc, there's an implied 92.63% upside for AbCellera Biologics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Stifel
Keybanc
Piper Sandler
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AbCellera Biologics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/22/2024 | ABCL | Buy Now | AbCellera Biologics | $3.98 | — | Benchmark | Robert Wasserman | — | Upgrade | Hold → Buy | Get Alert |
| 02/21/2024 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 327.14% | Stifel | Stephen Willey | $21 → $17 | Maintains | Buy | Get Alert |
| 12/05/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 50.75% | Keybanc | Scott Schoenhaus | → $6 | Initiates | → Overweight | Get Alert |
| 10/13/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 402.51% | Piper Sandler | Allison Bratzel | → $20 | Assumes | → Overweight | Get Alert |
| 08/31/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 201.51% | Benchmark | Robert Wasserman | $20 → $12 | Maintains | Buy | Get Alert |
| 08/04/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 503.02% | Goldman Sachs | Andrea Tan | $27 → $24 | Maintains | Buy | Get Alert |
| 05/05/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 603.52% | Credit Suisse | Tiago Fauth | $34 → $28 | Maintains | Outperform | Get Alert |
| 02/28/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | — | Cowen & Co. | Steven Mah | — | Initiates | → Outperform | Get Alert |
| 02/22/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 704.02% | BMO Capital | Gary Nachman | $40 → $32 | Maintains | Outperform | Get Alert |
| 02/22/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 754.27% | Credit Suisse | Tiago Fauth | → $34 | Reiterates | → Outperform | Get Alert |
| 01/06/2023 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 352.26% | SVB Leerink | Puneet Souda | $20 → $18 | Maintains | Outperform | Get Alert |
| 12/15/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 653.77% | Goldman Sachs | Andrea Tan | → $30 | Initiates | → Buy | Get Alert |
| 11/16/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 628.64% | Truist Securities | Robyn Karnauskas | → $29 | Initiates | → Buy | Get Alert |
| 11/09/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 402.51% | SVB Leerink | Puneet Souda | $13 → $20 | Maintains | Outperform | Get Alert |
| 08/10/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 754.27% | Credit Suisse | Tiago Fauth | $40 → $34 | Maintains | Outperform | Get Alert |
| 07/26/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 452.76% | Piper Sandler | Do Kim | $21 → $22 | Maintains | Overweight | Get Alert |
| 05/11/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 427.64% | Piper Sandler | Do Kim | $28 → $21 | Maintains | Overweight | Get Alert |
| 05/11/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 251.76% | SVB Leerink | Puneet Souda | $20 → $14 | Maintains | Outperform | Get Alert |
| 02/25/2022 | ABCL | Buy Now | AbCellera Biologics | $3.98 | 905.03% | Credit Suisse | Tiago Fauth | $39 → $40 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for AbCellera Biologics (ABCL)?
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on February 22, 2024. The analyst firm set a price target for $0.00 expecting ABCL to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbCellera Biologics (ABCL)?
The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics upgraded their buy rating.
When was the last upgrade for AbCellera Biologics (ABCL)?
The last upgrade for AbCellera Biologics Inc happened on February 22, 2024 when Benchmark raised their price target to N/A. Benchmark previously had a hold for AbCellera Biologics Inc.
When was the last downgrade for AbCellera Biologics (ABCL)?
There is no last downgrade for AbCellera Biologics.
When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.
Is the Analyst Rating AbCellera Biologics (ABCL) correct?
While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a upgraded with a price target of $0.00 to $0.00. The current price AbCellera Biologics (ABCL) is trading at is $3.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.